Monday, June 29, 2026
The last Monday before the July 4th holiday week — expect a thinner news cycle ahead as the industry heads into the long weekend.
This week’s signal sits at the intersection of consolidation and discipline. The robotics shakeout claimed another platform as Karl Storz pulled the plug on its Asensus inheritance, while H.B. Fuller’s move into surgical adhesives showed deal appetite is reaching well outside the usual medtech roster. Underneath the M&A, the post-market story kept its grip: a fresh bleeding-risk alert and the still-reverberating Zoll warning letter are reminders that quality systems, not technology, remain the industry’s exposed flank. And in diabetes, the sensor wars went transatlantic.
8 things to watch this week:
1. 🤖 Karl Storz scraps Asensus robotics platform, cuts 108 jobs in North Carolina
Two years after acquiring Asensus to advance its next-gen Luna robotic system, Karl Storz is discontinuing Luna development, phasing out the Senhance platform, and retiring the Asensus brand entirely, with layoffs including roughly 30 engineers. The reversal is a stark signal that even well-funded soft-tissue robotics programs are struggling to find a path against Intuitive’s entrenched lead — and that “robotics as a layer” is winning over robotics as a standalone bet.
MedTech Dive
2. 🩸 MiniMed launches Abbott-made Instinct sensors across Europe
The newly independent MiniMed rolled out its 780G and Go systems paired with Abbott’s 15-day Instinct sensor in Europe, opening its pump franchise to roughly 4.5 million Abbott CGM users it previously couldn’t reach. The Medtronic-Abbott collaboration is a notable détente between two diabetes-tech rivals — and a reminder that, with 70% of MiniMed’s sales coming from overseas, the European installed base is the real battleground.
Drug Delivery Business News
3. 🧭 Most device companies don't fail on technology. They fail on sequencing.
Before you raise, launch a pilot, or scale revenue, small commercialization mistakes can cost months — or millions. RŌG Health's Commercial Readiness Check is a 2-minute diagnostic that shows whether your company is prepared for its next milestone, and points you to where the gaps are.
Sponsored by RŌG Health
4. 🔬 Diabetes-tech execs weigh the promise and problem of multi-analyte sensors
Leaders from Abbott, PercuSense and Biolinq laid out where continuous sensing goes next — beyond glucose to ketones, lactate and potassium — on the heels of Abbott’s CE mark for its dual glucose-ketone Libre Duo. The strategic tension is data, not chemistry: each new analyte generates a stream that clinicians and payers don’t yet have workflows to act on, raising the question of who owns the burden of interpretation.
MedTech Dive
5. 💰 H.B. Fuller bids ~$942M for surgical-adhesives maker Advanced Medical Solutions
The world’s largest pure-play adhesives company agreed to a £715M ($942.5M) cash takeover of UK-listed AMS, adding tissue bonding adhesives, dressings and biosurgicals and expanding its addressable market by $15B. It’s a telling sign of where the smart money sees durable margins: an industrial player paying a 35% premium to buy its way into the regulatory-moated medical segment rather than build.
Medical Device Network
6. 💲 Medtronic names its first-ever CFO of innovation
Medtronic hired 22-year J&J veteran Eric Lenard into the newly created role of VP and CFO for innovation, development and quality, putting finance leadership directly inside the R&D engine. The move — amid a year of restructuring including the MiniMed spinoff and a new Ireland software hub — signals an attempt to bring capital-allocation discipline to the pipeline as the company pivots to “offense” on M&A.
MassDevice
7. ⚠️ J&J’s Abiomed warns of bleeding risk in catheter-introducer devices
Abiomed and manufacturing partner Oscor flagged a bleeding risk tied to devices used to introduce catheters into the body — the latest in a long string of post-market actions touching J&J’s circulatory-support franchise. For operators, the cadence of alerts around high-acuity cardiac devices keeps the spotlight on supplier quality and vigilance reporting as the real differentiators.
Cardiovascular Business
8. 🏭 Zoll’s FDA warning letter exposes a years-long CAPA breakdown
The FDA’s warning letter to Zoll detailed how a ventilator nonconformance coded as “user error” delayed a Class I recall by weeks, with the agency citing repeated inadequate responses across nearly a year. Notably, the FDA reminded Zoll that corrective actions must now comply with the QMSR that took effect February 2 — a preview of how the new quality framework will be enforced against legacy violations.
MD+DI
Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.